Lirilumab
Lirilumab is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3.
This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.A phase 2 clinical trial for acute myeloid leukemia was terminated early in 2017.
It was registered for a trial for squamous cell carcinoma of the head and neck, but it may be abandoned.
nine clinical trials of lirilumab are registered as active.
